drugset / Trial / NCT07674654

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

NCT07674654

Phase 3 Not yet recruiting 1000 enrolled Kallyope Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.

Timeline

Start
2026-07
Primary completion
2028-06
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Elismetrep Small molecule 10 mg Oral
Subject Elismetrep Small molecule 20 mg Oral

Indications